Division of Rheumatology, Department of Internal Medicine, Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea.
Ann Med. 2023 Dec;55(1):1009-1017. doi: 10.1080/07853890.2023.2187076.
The aim of this study was to define the clinical, histopathologic, and prognostic features associated with simultaneous positivity for anti-dsDNA, -nucleosome, and -histone antibodies (3-pos) in Korean patients with biopsy-proven lupus nephritis (LN).
The 102 patients included in the study had undergone kidney biopsy prior to the start of induction treatment, were treated with immunosuppressives, and followed-up for >12 months.
In total, 44 (43.1%) of the 102 LN patients were 3-pos. Patients with 3-pos had a higher SLEDAI-2K score ( = .002), lower lymphocyte count ( = .004), and higher rates of proteinuria > 3.5 g/24 h ( = .039) and positivity for urinary sediments ( = .005) at the time of renal biopsy than non-3-pos patients. 3-pos patients had a more proliferative form of LN ( = .045) in the renal histopathologic findings, and as co-positivity gradually increased from 0 to 3, the total activity score in the renal biopsy findings increased significantly ( = .033). In addition, 3-pos patients had a more rapid eGFR decline than non-3-pos patients after a follow-up of 83.2 months ( = .016).
Our findings suggest that 3-pos is related to severe LN and that 3-pos patients are more likely to experience a rapid decline of renal function than non-3-pos patients.KEY MESSAGEPatients with co-positivity for anti-dsDNA, -nucleosome, and -histone antibodies (3-pos) had higher disease activity and a worse renal histopathology than those without co-positivity.3-pos patients had a more rapid decline of renal function than non-3-pos patients.
本研究旨在定义与韩国经活检证实的狼疮肾炎(LN)患者同时存在抗 dsDNA、-核小体和-组蛋白抗体阳性(3 阳性)相关的临床、组织病理学和预后特征。
本研究纳入的 102 例患者在开始诱导治疗前均接受了肾活检,接受了免疫抑制剂治疗,并随访时间>12 个月。
总共,44 例(43.1%)LN 患者为 3 阳性。3 阳性患者的 SLEDAI-2K 评分更高(=.002)、淋巴细胞计数更低(=.004)、蛋白尿>3.5 g/24 h 的发生率更高(=.039)和尿沉渣阳性率更高(=.005)。3 阳性患者的肾脏组织病理学表现为更具增生性的 LN(=.045),并且随着 co-阳性逐渐从 0 增加到 3,肾脏活检结果的总活动评分显著增加(=.033)。此外,在随访 83.2 个月后,3 阳性患者的 eGFR 下降速度比非 3 阳性患者更快(=.016)。
我们的研究结果表明,3 阳性与严重的 LN 相关,3 阳性患者比非 3 阳性患者更有可能出现肾功能迅速下降。
与非 co 阳性患者相比,抗 dsDNA、-核小体和-组蛋白抗体 co 阳性(3 阳性)的患者疾病活动度更高,肾脏组织病理学更差。
3 阳性患者的肾功能下降速度比非 3 阳性患者更快。